To further validate the protective effect of MCM@MOF@irisin nanotherapeutics on I/R injury to reduce the progression of AKI to CKD, saline, irisin, or MCM@MOF@irisin was intravenously administered in I/R mice four times during the first week with a two‐day interval between each administration. This evidence concerns the gene FNDC5 and acute kidney injury.